Compare SYSCO Corporation (SYY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs TG Therapeutics Inc — how do they compare? SYSCO Corporation trades at $83.6 (market cap $40.53B), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: SYSCO Corporation is far larger — about 5.3× TG Therapeutics Inc's market cap, and SYSCO Corporation pays a 2.6% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SYY | TGTX | |
|---|---|---|
Market Cap | $40.53B | $7.58B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $59.06 |
52-Week Low | $69.30 | $26.94 |
Enterprise Value | $53.71B | $7.78B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYY trades at $83.55, down 0.84% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent Q2 2026 earnings beat expectations with EPS of $1.53 versus $1.51 expected, driven by volume growth and cost efficiencies. Revenue reached $81.37B in 2025, though net income margin dipped to 2.08%. The company maintains a dividend with a $0.55 payment scheduled for July 2026.
Outlook is positive with analyst consensus at Buy (60% of 30 analysts) and a $88.25 price target, offering ~5.6% upside. Risks include margin pressure from inflation and supply chain disruptions, as seen in recent lettuce sourcing halts due to safety concerns. Strong cash flow growth supports debt management and shareholder returns.
TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.
The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
